Adults 55 Years and Older with Multiple Sclerosis (MS) Treated with Ocrelizumab: Characteristics and Outcomes Over More Than 13,000 Person-Months (P10-1.013)
To determine the clinical features, infection incidence, treatment persistence, and immunoglobulin levels in older adults treated with Ocrelizumab for MS.
Authors
- Farrah Jasmine Mateen (ORCID: https://orcid.org/0000-0002-4293-8115)
- Raphael Scheu
- Maya L Mastick (ORCID: https://orcid.org/0009-0003-3757-1587)
- Seungwon Lee (ORCID: https://orcid.org/0000-0002-0413-0510)
Institutions
- University of Cambridge (GB)
- Harvard University Press (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210949
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47